Login to Your Account

Interest in InterMune?

Gilead Going 'MAb' Via $225M Buyout of Early Stage Arresto

By Jennifer Boggs

Tuesday, December 21, 2010
Six months after adding a kinase program to its pipeline by acquiring CGI Pharmaceuticals Inc., Gilead Sciences Inc. picked up its first monoclonal antibody product in another early stage deal, buying out privately held Arresto Biosciences Inc. for $225 million in cash plus future milestones tied to sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription